Agilent Technologies, Inc. (NYSE:A) Shares Sold by Bamco Inc. NY

Bamco Inc. NY decreased its holdings in Agilent Technologies, Inc. (NYSE:A) by 4.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 78,663 shares of the medical research company’s stock after selling 3,698 shares during the quarter. Bamco Inc. NY’s holdings in Agilent Technologies were worth $11,680,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA grew its holdings in Agilent Technologies by 5.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after acquiring an additional 809,149 shares in the last quarter. FMR LLC grew its stake in Agilent Technologies by 62.2% in the third quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock worth $191,193,000 after purchasing an additional 493,947 shares in the last quarter. Marshall Wace LLP increased its holdings in Agilent Technologies by 48.6% in the second quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after buying an additional 313,155 shares during the last quarter. Jennison Associates LLC raised its stake in Agilent Technologies by 63.3% during the third quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock valued at $87,075,000 after buying an additional 227,431 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its holdings in Agilent Technologies by 8.2% during the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock worth $396,088,000 after buying an additional 203,234 shares during the last quarter. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at $5,801,595. This trade represents a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.33% of the stock is owned by insiders.

Agilent Technologies Trading Up 1.2 %

NYSE:A opened at $139.60 on Tuesday. The stock has a market cap of $40.11 billion, a price-to-earnings ratio of 31.58, a PEG ratio of 4.37 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 2.09. Agilent Technologies, Inc. has a 1 year low of $124.16 and a 1 year high of $155.35. The business has a fifty day moving average of $137.60 and a 200-day moving average of $137.15.

Agilent Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.248 per share. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $0.99 annualized dividend and a yield of 0.71%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.40%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. UBS Group boosted their price target on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. TD Cowen boosted their target price on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. JPMorgan Chase & Co. reduced their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. Evercore ISI boosted their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $151.00 price objective on shares of Agilent Technologies in a research note on Monday, August 26th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $143.40.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.